Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous lidocaine for inflammation reduction during elective cardiac surgery with cardiopulmonary bypass
2025-523534-11-00Phase 2Authorised
- Sponsor
- Providence Little Company of Mary Medical Center San Pedro
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lidocaine in Systemic Inflammatory Response Syndrome (SIRS) (2 arms), sponsored by Providence Little Company of Mary Medical Center San Pedro. Primary endpoint: Interleukin-6 level at 6 hours postoperatively. Planned start Dec 2025; status: authorised.
02
Drugs
lidocaine
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on 2025-523534-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523534-11-00.